AUG 31, 2021 7:00 AM PDT

Convalescent Plasma Therapy for COVID-19 Doesn't Work

WRITTEN BY: Tara Fernandez

After encountering an infectious agent, the immune system begins churning out antibodies—Y-shaped warriors that neutralize pathogens—into the blood circulation. In theory, donor blood from patients who have recovered from an infection could be used therapeutically, helping those experiencing severe symptoms recover.

In the case of COVID-19, the U.S. Food and Drug Administration (FDA) granted emergency authorization for convalescent plasma therapy earlier on in the pandemic. This therapy was targeted towards patients in hospitals suffering from COVID-19, particularly those who were immunocompromised. Since its authorization, tens of thousands of patients in the U.S. have been administered convalescent plasma therapy, despite the lack of clinical trial data to support the efficacy of the treatment.

Now, a recent study by Stanford researchers has revealed the harsh reality of convalescent plasma therapy for COVID-19: it doesn’t work.

A clinical trial called C3P0 was initiated by researchers at the National Institutes of Health around a year ago. The study aimed to understand how high-risk patients (such as those with underlying medical conditions such as asthma and Type 2 diabetes) would benefit from convalescent plasma therapy at the early stages of COVID-19 infection. This subset of patients is especially prone to progressing on to more severe, life-threatening symptoms of the disease, and early on during the pandemic, there were very few clinical options to support their recovery.

In February—despite only enrolling around 500 of the targeted 900 study participants—the C3PO study was terminated after researchers found no benefit of convalescent plasma at resisting severe COVID-19 symptoms compared to the placebo. 

Initially, researchers involved in the study estimated that plasma therapy might slash the risk of COVID-19 progression by around 10 percent. However, the clinical data collected from C3PO revealed that this number was under two percent.

“While this trial was negative, we need to continue this research to understand when passive immunotherapy such as convalescent plasma can be effective in treating emerging infectious diseases,” commented Kevin Schulman, one of the lead investigators involved in this work.

 

Source: The New England Journal of Medicine, Stanford Medicine.


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
JUN 11, 2021
Cannabis Sciences
Does Cannabis Interact with the COVID Vaccine?
JUN 11, 2021
Does Cannabis Interact with the COVID Vaccine?
As of June 10th 2021, 43% of people in the US aged 12 and over have been fully vaccinated for COVID-19, with 5 ...
JUN 29, 2021
Immunology
The Heartbreaking Nature of COVID Revealed
JUN 29, 2021
The Heartbreaking Nature of COVID Revealed
Researchers at the Washington University School are getting to the root of heart damage resulting from COVID-19 infectio ...
JUL 20, 2021
Coronavirus
Pregnant and lactating people can pass COVID-19 antibodies from the vaccine
JUL 20, 2021
Pregnant and lactating people can pass COVID-19 antibodies from the vaccine
New research found that both pregnant and lactating people who receive the COVID-19 vaccine can pass antibodies to their ...
AUG 13, 2021
Cancer
Ultrasound Triggers Immunotherapy to Destroy Tumors
AUG 13, 2021
Ultrasound Triggers Immunotherapy to Destroy Tumors
An immunotherapy engineered to be triggered by ultrasound beams significantly slows the growth of cancerous tumors in mi ...
AUG 20, 2021
Drug Discovery & Development
One Vaccine to Rule Them All: Researchers One Step Closer to Universal Vaccine
AUG 20, 2021
One Vaccine to Rule Them All: Researchers One Step Closer to Universal Vaccine
Researchers have identified two antibodies that can protect animals from diseases caused by alphaviruses, which are RNA ...
AUG 25, 2021
Cell & Molecular Biology
Sino Biological's Listing on the Shenzhen Stock Exchange
AUG 25, 2021
Sino Biological's Listing on the Shenzhen Stock Exchange
China, August 16, 2021 - Sino Biological, Inc. (“Sino Biological” or the “Company”), a biot ...
Loading Comments...